Subcutaneous Tocilizumab in Monotherapy or in Combination with DMARD in Patients with Moderate to Severe Active Rheumatoid Arthritis: Observational Study to Describe Real-World Drug Retention Rate at 12 Months, Interim Analysis - Université de Bretagne Occidentale
Conference Poster Year : 2018

Subcutaneous Tocilizumab in Monotherapy or in Combination with DMARD in Patients with Moderate to Severe Active Rheumatoid Arthritis: Observational Study to Describe Real-World Drug Retention Rate at 12 Months, Interim Analysis

Domains

Life Sciences [q-bio]

Geneviève Michel  : Connect in order to contact the contributor

https://hal.univ-brest.fr/hal-01950797

Submitted on : Tuesday, December 11, 2018-9:26:15 AM

Last modification on : Wednesday, October 30, 2024-6:08:04 PM

No file

Dates and versions

hal-01950797 , version 1 (11-12-2018)

Identifiers

  • HAL Id : hal-01950797 , version 1

Cite

P. Hilliquin, T Barnetche, G Baudens, R. Niarra, I Idier, et al.. Subcutaneous Tocilizumab in Monotherapy or in Combination with DMARD in Patients with Moderate to Severe Active Rheumatoid Arthritis: Observational Study to Describe Real-World Drug Retention Rate at 12 Months, Interim Analysis. ACR/ARHP Annual Meeting, Oct 2018, Chicago, France. 70 (suppl 10) (Abstract 573), Arthritis Rheumatology. ⟨hal-01950797⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

UNIV-BREST IMMUNO IBSAM
33 View
0 Download

Share

More